Finance News – Novo Nordisk
What is your interest today?
- ABC News Business
- BBC Business
- Business Insider Markets
- CBC Business
- City A.M.
- CNBC Business
- CoinDesk
- Cointelegraph
- Crypto News
- CryptoSlate
- Decrypt
- Economic Times Markets
- Euronews Business
- Financial Post Top Stories
- Financial Times
- Finextra Crypto
- Finextra Market
- Finextra Wealth
- Globe and Mail Investing
- Investing.com Global Markets
- Investing.com Global Mkts
- Investopedia
- Kiplinger
- MarketWatch MarketPulse
- MarketWatch Top Stories
- Quartz
- Sky News Money
- Sydney Morning Herald Biz
- Sydney Morning Herald Business
- TechCrunch Fintech
- The Block
- The Guardian – Business
- WSJ Markets News
Hims & Hers Stock Plunges 35% as Novo Nordisk Ends Partnership, Citing 'Illegal' Practices
The termination of the collaboration by Novo Nordisk has led to a significant decline in Hims & Hers' market value, reflecting investor concerns over the allegations and potential...
Read Full Article →Hims & Hers Stock Plunges 33% as Novo Nordisk Ends Partnership, Citing 'Illegal' Practices
The termination of the collaboration with Novo Nordisk has led to a significant decline in Hims & Hers’ market value, reflecting investor concerns about the company’s operational c...
Read Full Article →Hims & Hers’ stock plunges. Here’s why Wegovy parent ended its partnership with the company.
The termination of the collaboration between Hims & Hers and Novo Nordisk triggered a substantial decline in Hims & Hers’ share value, reflecting investor concerns about the compan...
Read Full Article →Novo Nordisk Stock Sinks as Latest Weight-Loss Drug Trial Disappoints
Shares of Novo Nordisk declined following underwhelming results from their recent obesity treatment study, raising concerns among investors about the drug’s potential market impact...
Read Full Article →A $250 mistake seems set to cost Ozempic maker Novo Nordisk billions
Novo Nordisk is expected to face substantial financial losses as Canada prepares to introduce generic alternatives of its weight loss medication due to the company’s failure to mai...
Read Full Article →After ousting CEO, Novo Nordisk reclaims crown as largest European company
Following the unexpected leadership change, the pharmaceutical company regained its position as the top European firm based on market value, highlighting its strong financial stand...
Read Full Article →Healthy Returns: Ozempic, Wegovy linked to rare cases of serious eye condition
Novo Nordisk’s medications associated with uncommon but severe eye issues may impact the company’s valuation, as emerging health technology firms continue to gain significant inves...
Read Full Article →Novo Nordisk Stock Climbs on Report of Activist Investor Parvus Building Stake
Shares of Novo Nordisk rose following news that activist investor Parvus has been gradually acquiring a notable portion of the company’s equity, potentially influencing future stra...
Read Full Article →Activist hedge fund builds stake in Ozempic-maker Novo Nordisk
An investment firm has increased its holdings in the Danish pharmaceutical company known for its diabetes treatment, signaling confidence amid leadership changes and recent decline...
Read Full Article →How Ozempic maker Novo Nordisk fell behind Eli Lilly in the weight loss drug race
Despite its initial leadership in the growing weight loss medication sector, Novo Nordisk has recently experienced a decline in market share compared to Eli Lilly, affecting its fi...
Read Full Article →Cigna announces new deal for copay caps on Eli Lilly and Novo Nordisk weight loss drugs
Cigna’s Evernorth division reached an agreement that aims to reduce out-of-pocket expenses for employers and employees on certain weight management medications from Eli Lilly and N...
Read Full Article →Novo Nordisk is betting on a CEO shakeup to regain its weight loss drug edge over Eli Lilly
Novo Nordisk’s leadership change aims to strengthen its position in the weight loss market, improve competitive standing against Eli Lilly, and address upcoming industry challenges...
Read Full Article →Ozempic-maker Novo Nordisk ousts CEO after shares plummet
Novo Nordisk's decision to replace its CEO follows a significant decline in the company’s stock value, underscoring the financial impact of recent market challenges on the pharmace...
Read Full Article →Novo Nordisk CEO steps down amid growing competition for weight loss drugs
The departure of the longstanding CEO coincides with increased market challenges in the weight management sector, potentially impacting the company's strategic direction and future...
Read Full Article →Novo Nordisk's CEO is out after the Ozempic maker's stock dropped 50% in a year
Novo Nordisk announced that its CEO, Lars Fruergaard Jørgensen, will resign following a significant decline in the company’s market value linked to challenges faced by its key diab...
Read Full Article →Novo Nordisk CEO to step down as Wegovy maker faces growing competition
The departure of the CEO at the Danish pharmaceutical company is expected to impact investor confidence as the firm navigates increased market rivalry and aims to sustain its finan...
Read Full Article →Ozempic maker Novo Nordisk boots CEO over stock-price fall
The departure of Novo Nordisk's CEO follows a decline in the company's market value, highlighting investor concerns about future financial performance in the competitive pharmaceut...
Read Full Article →This biotech’s stock rockets on oral obesity-drug partnership with Wegovy parent
The collaboration between Novo Nordisk and Septerna is expected to enhance their pipeline in obesity and diabetes therapies, potentially increasing market value and investor confid...
Read Full Article →Eli Lilly's Zepbound beat Novo Nordisk’s Wegovy in a big weight loss drug study
The superior results of Eli Lilly’s medication compared to Novo Nordisk’s in the recent trial may influence market dynamics and investor confidence within the competitive obesity t...
Read Full Article →Here’s how much extra weight is lost with Zepbound over Wegovy
A recent comparison of two popular weight-loss medications highlighted a measurable difference in effectiveness, potentially influencing market share and revenue for the companies...
Read Full Article →Novo Nordisk cuts guidance as weight-loss drug market competition grows
Novo Nordisk's quarterly results surpassed expectations, yet the company reduced its future growth projections due to increasing rivalry within the weight management pharmaceutical...
Read Full Article →Novo Nordisk shares are rising after the company cut its outlook. It’s been that kind of year.
Despite lowering its profit forecast, Novo Nordisk’s stock value is increasing, reflecting investor confidence amid a challenging market environment this year.
Read Full Article →Wegovy maker Novo Nordisk cuts profit forecast as US prescriptions tail off
Novo Nordisk's reduced earnings outlook reflects challenges in maintaining sales momentum for its obesity treatment, as competitive pressures from US rivals increasingly impact its...
Read Full Article →Novo Nordisk cuts 2025 guidance on weaker-than-expected Wegovy sales, posts first-quarter profit bea...
Despite reporting higher-than-anticipated first-quarter earnings, Novo Nordisk adjusted its 2025 revenue outlook downward due to slower demand for Wegovy, impacting overall financi...
Read Full Article →CVS to boost access to Novo Nordisk's weight loss treatment Wegovy for patients on its drug plans
Starting July 1, Caremark will prioritize Wegovy on its formulary, improving accessibility for patients on its drug plans and potentially increasing the treatment's market presence...
Read Full Article →